Back to results
US 10,947,511 B2Granted
Differentiation of human embryonic stem cells into pancreatic endocrine cells using thyroid hormone and/or alk5, an inhibitor of tgf-beta type 1 receptor
AssigneeJanssen Biotech, Inc.
InventorAlireza Rezania
Life of this patent
Estimating the term…
Abstract
The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both.
Claims12
An in vitro cell culture for differentiating cells derived from human pluripotent stem cells comprising:
- a) a culture vessel;
- b) a volume of differentiation medium;
- and
- c) a population of differentiated cells derived from human pluripotent stem cells wherein at least ten percent of said differentiated cells co-express PDX1, NKX6.1 and HB9, wherein said differentiation medium comprises a growth medium supplemented with a thyroid hormone selected from the group consisting of triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine and mixtures thereof, or
- both the thyroid hormone and ALK5 inhibitor.
2 more elements
An in vitro cell culture comprising a population of differentiated human pluripotent stem cells expressing pancreatic endocrine cell markers wherein at least ten percent of said cells express HB9, PDX1 and NKX6.1.
Dependencies are inferred from the claim text.